Sanli Pharmaceutical: Abnormal stock trading fluctuations, no major undisclosed matters requiring disclosure

Sanli Pharmaceutical announced that the company's stock closing price deviation accumulated over 20% during three consecutive trading days on September 10, September 11, and September 14, 2026, constituting an abnormal fluctuation in stock trading. Upon self-examination and verification with the controlling shareholder and actual controller, as of the date of this announcement, there is no major information that should be disclosed but has not been disclosed. The company's current production and operations are normal, and it is not involved in market hotspot concepts. The directors, supervisors, senior management, and controlling shareholder did not buy or sell the company's stock during the period of abnormal fluctuation. The company's disclosed 2026 private placement of A-shares to specific targets still requires deliberation and review, and there is uncertainty. Investors are kindly reminded to pay attention to investment risks.